

# Vipul Jairath

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2918044/vipul-jairath-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

150  
papers

3,190  
citations

32  
h-index

52  
g-index

179  
ext. papers

4,421  
ext. citations

6.6  
avg, IF

5.61  
L-index

#	Paper	IF	Citations
150	P457 Long-term cumulative safety of ustekinumab in bionative patients with Crohn's Disease and Ulcerative Colitis. <i>Journal of Crohns and Colitis</i> , <b>2022</b> , 16, i434-i435	1.5	
149	Janus Kinase Inhibitors for the Management of Patients With Inflammatory Bowel Disease.. <i>Gastroenterology and Hepatology</i> , <b>2022</b> , 18, 14-27	0.7	
148	Comparison of Risk Scores for Lower Gastrointestinal Bleeding. <i>JAMA Network Open</i> , <b>2022</b> , 5, e2214253	10.4	0
147	Updates in Clinical, Endoscopic, and Histologic Composite and Co-primary Endpoints for Clinical Trials in Inflammatory Bowel Disease. <i>Current Treatment Options in Gastroenterology</i> , <b>2021</b> , 19, 608	2.5	
146	Responsiveness of a Histologic Scoring System Compared With Peak Eosinophil Count in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , <b>2021</b> ,	0.7	1
145	No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn's Disease Treated with Anti-metabolite Therapy. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 1	4	1
144	A high-dose 24-hour tranexamic acid infusion for the treatment of significant gastrointestinal bleeding: HALT-IT RCT. <i>Health Technology Assessment</i> , <b>2021</b> , 25, 1-86	4.4	0
143	Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 2031-2045	6.9	20
142	Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 1	4	0
141	Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2021</b> , 15, 711-722	4.2	1
140	The Impact of Multidisciplinary Conferences on Treatment Plans for Patients With Inflammatory Bowel Disease in a Tertiary Canadian Centre. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2021</b> , 4, 284-289	0.5	
139	Impact of COVID-19 on Inflammatory Bowel Disease Clinical Trial Recruitment: A Global Survey of Principal Investigators. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, e98	4.5	0
138	OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn's Disease: The SEAVUE study. <i>Journal of Crohns and Colitis</i> , <b>2021</b> , 15, S001-S002	1.5	6
137	Vedolizumab-Induced Endoscopic and Histologic Improvement in Gastric Menetrier's Disease in a Patient With Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, e132-e133	4.5	1
136	An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials. <i>Gastroenterology</i> , <b>2021</b> , 160, 2291-2302	13.3	10
135	Drug-induced Lupus Associated With Vedolizumab in a Patient with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, e47-e48	4.5	2
134	High-Dose Rescue Tofacitinib Prevented Inpatient Colectomy in Acute Severe Ulcerative Colitis Refractory to Anti-TNF. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, e59-e60	4.5	1

133	An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 784-793	6.1	3
132	Tofacitinib for the Treatment of Three Immune-mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, e65	4.5	4
131	Spatial Evolution of Histologic and Endoscopic Healing in the Left and Right Colon in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	1
130	Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> ,	11.5	4
129	Challenges and Opportunities in IBD Clinical Trial Design. <i>Gastroenterology</i> , <b>2021</b> , 161, 400-404	13.3	1
128	A Summary of the Meetings of the Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS) International Multidisciplinary Consensus. <i>Gastroenterology</i> , <b>2021</b> , 161, 778-784	13.3	
127	Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis-authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 957-958	6.1	
126	An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 1108-1117	6.1	2
125	Adalimumab for maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , <b>2020</b> , 5, CD012877	5.2	1
124	Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 885-894	0.7	6
123	No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 481-491	6.1	5
122	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2952-2961.e3	6.0	21
121	Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , <b>2020</b> , 65, 2354-2372	4	14
120	Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis. <i>The Cochrane Library</i> , <b>2020</b> , 1, CD012381	5.2	3
119	Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?. <i>Rheumatology and Therapy</i> , <b>2020</b> , 7, 35-64	4.4	29
118	Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 1574-1582	6.1	4
117	Early Combined Immunosuppression Reduces Complications in Long-standing Crohn's Disease: A Post Hoc Analysis of REACT. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> ,	6.9	3
116	Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 1121-1132.e2	6.9	8

115	Global burden of inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 2-3	18.8	53
114	Reporting of randomized factorial trials was frequently inadequate. <i>Journal of Clinical Epidemiology</i> , <b>2020</b> , 117, 52-59	5.7	10
113	Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 424-431.e7	6.9	9
112	Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 435-445	6.1	11
111	Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design. <i>Gastroenterology</i> , <b>2020</b> , 159, 2013-2018.e7	13.3	3
110	Novel Therapeutics for the Treatment of IBD: Current Status and Future Directions. <i>Current Treatment Options in Gastroenterology</i> , <b>2020</b> , 18, 442-461	2.5	1
109	Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 1008-1016	6.1	7
108	Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease. <i>The Cochrane Library</i> , <b>2020</b> , 10, CD013256	5.2	2
107	Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 69-81.e3	6.9	79
106	Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 1047-1066	6.1	10
105	Declining hospitalisation and surgical intervention rates in patients with Crohn's disease: a population-based cohort. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 1086-1093	6.1	13
104	Development and Validation of a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn's Disease. <i>Gastroenterology</i> , <b>2019</b> , 157, 1233-1244.e5	13.3	28
103	Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 5-23	6.1	43
102	Most noninferiority trials were not designed to preserve active comparator treatment effects. <i>Journal of Clinical Epidemiology</i> , <b>2019</b> , 110, 82-89	5.7	8
101	Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 1401-1409	6.1	10
100	Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 1188-1194	6.1	14
99	Efficacy of Endoscopic Dilatation of Gastroduodenal Crohn's Disease Strictures: A Systematic Review and Meta-Analysis of Individual Patient Data. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2514-2522.e8	6.9	21
98	Concomitant Use of Aminosalicylates Is Not Associated With Improved Outcomes in Patients With Ulcerative Colitis Escalated to Vedolizumab. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2374-2378.e2	6.9	11

97	Diagnosis and management of acute lower gastrointestinal bleeding: guidelines from the British Society of Gastroenterology. <i>Gut</i> , <b>2019</b> , 68, 776-789	19.2	92
96	Outcomes following restrictive or liberal red blood cell transfusion in patients with lower gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 919-925	6.1	7
95	Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. <i>Gut</i> , <b>2019</b> , 68, 1162-1168	19.2	27
94	Letter: pre-operative anti-TNF therapy in Crohn's disease is not associated with increased complications following elective surgery. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 467-468	6.1	1
93	No increased risk of nephrotoxicity associated with 5-aminosalicylic acid in IBD: a population-based cohort and nested case-control study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 416-424	6.1	7
92	Letter: immunogenicity of anti-TNF in elderly IBD patients-authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 337	6.1	
91	Tranexamic acid for acute gastrointestinal bleeding (the HALT-IT trial): statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial. <i>Trials</i> , <b>2019</b> , 20, 467	2.8	6
90	Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease. <i>The Cochrane Library</i> , <b>2019</b> ,	5.2	2
89	Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 1100-1111	6.1	11
88	What is the role of histopathology in the evaluation of disease activity in Crohn's disease?. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2019</b> , 38-39, 101601	2.5	5
87	Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 733-745	18.7	22
86	Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 364-374	6.1	1
85	Comparative outcomes in patients with ulcer- vs non-ulcer-related acute upper gastrointestinal bleeding in the United Kingdom: a nationwide cohort of 4474 patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 537-545	6.1	5
84	A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 63-70	18.8	11
83	Rebleeding and Mortality After Lower Gastrointestinal Bleeding in Patients Taking Antiplatelets or Anticoagulants. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1276-1284.e3	6.9	17
82	Acute lower GI bleeding in the UK: patient characteristics, interventions and outcomes in the first nationwide audit. <i>Gut</i> , <b>2018</b> , 67, 654-662	19.2	85
81	Reliability of histologic assessment in patients with eosinophilic oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 940-950	6.1	30
80	Efficacy of Medical Therapies for Fistulizing Crohn's Disease: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1879-1892	6.9	70

79	Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease. <i>Current Treatment Options in Gastroenterology</i> , <b>2018</b> , 16, 129-146	2.5	44
78	Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance Enterography. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 440-449	4.5	25
77	Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 1578-1596	6.1	19
76	Heterogeneity in Definitions of Efficacy and Safety Endpoints For Clinical Trials of Crohn's Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1407-1419.e22	6.9	29
75	Disease activity indices in coeliac disease: systematic review and recommendations for clinical trials. <i>Gut</i> , <b>2018</b> , 67, 61-69	19.2	22
74	Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease. <i>Journal of Crohns and Colitis</i> , <b>2018</b> , 12, 167-177	1.5	31
73	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 637-647.e13	6.9	27
72	The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?. <i>Journal of Crohns and Colitis</i> , <b>2018</b> , 12, 105-119	1.5	55
71	Physicians' Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , <b>2018</b> , 63, 2555-2563	4	6
70	Outcome pre-specification requires sufficient detail to guard against outcome switching in clinical trials: a case study. <i>Trials</i> , <b>2018</b> , 19, 265	2.8	6
69	P473 Contrasting the use of 5-ASA in patients with Ulcerative Colitis and Crohn's Disease: A cross-sectional analysis at a tertiary care IBD clinic. <i>Journal of Crohns and Colitis</i> , <b>2018</b> , 12, S343-S343	1.5	
68	Outcome measures in clinical trials of treatments for acute severe haemorrhage. <i>Trials</i> , <b>2018</b> , 19, 533	2.8	20
67	Loss of tolerance to glycoprotein 2 isoforms 1 and 4 is associated with Crohn's disease of the pouch. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 1251-1259	6.1	5
66	No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 1197-1205	0.7	31
65	The emerging role of histologic disease activity assessment in ulcerative colitis. <i>Gastrointestinal Endoscopy</i> , <b>2018</b> , 88, 887-898	5.2	53
64	Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 114-126	6.1	7
63	Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. <i>Gastrointestinal Endoscopy</i> , <b>2018</b> , 88, 360-369.e2	5.2	15
62	Evaluation of the effect of storage condition on cell extraction and flow cytometric analysis from intestinal biopsies. <i>Journal of Immunological Methods</i> , <b>2018</b> , 459, 50-54	2.5	2

61	Development and validation of a histological index for UC. <i>Gut</i> , <b>2017</b> , 66, 50-58	19.2	151
60	Review article: dose optimisation of infliximab for acute severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 617-630	6.1	50
59	Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 1021-1042	6.1	26
58	Restrictive versus liberal blood transfusion for gastrointestinal bleeding: a systematic review and meta-analysis of randomised controlled trials. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 354-360	18.8	80
57	Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 3-15	6.1	82
56	Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 213-224	6.1	151
55	Histologic scoring indices for evaluation of disease activity in ulcerative colitis. <i>The Cochrane Library</i> , <b>2017</b> , 5, CD011256	5.2	18
54	Letter: dose optimising infliximab in acute severe ulcerative colitis - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 1170-1171	6.1	0
53	Antibiotics for induction and maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , <b>2017</b> ,	5.2	78
52	Systematic Review: Disease Activity Indices in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1658-1669	0.7	23
51	The Evolution of Treatment Paradigms in Crohn's Disease: Beyond Better Drugs. <i>Gastroenterology Clinics of North America</i> , <b>2017</b> , 46, 661-677	4.4	7
50	Derivation and validation of a novel risk score for safe discharge after acute lower gastrointestinal bleeding: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 635-643	18.8	46
49	The development of a magnetic resonance imaging index for fistulising Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 516-528	6.1	28
48	Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. <i>Journal of Crohns and Colitis</i> , <b>2017</b> , 11, 246-255	1.5	13
47	Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. <i>The Cochrane Library</i> , <b>2017</b> , 9, CD011572	5.2	12
46	Infliximab for induction of remission in Crohn's disease. <i>The Cochrane Library</i> , <b>2017</b> ,	5.2	78
45	Placebo response and remission rates in randomised trials of induction and maintenance therapy for Crohn's disease. <i>The Cochrane Library</i> , <b>2017</b> ,	5.2	78
44	Adalimumab for maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , <b>2017</b> ,	5.2	1

43	Acute severe ulcerative colitis: from pathophysiology to clinical management. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2016</b> , 13, 654-664	24.2	80
42	Antibody development against biologic agents used for the treatment of inflammatory bowel disease and antibody prevention with immunosuppressives. <i>The Cochrane Library</i> , <b>2016</b> ,	5.2	1
41	Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition. <i>Journal of Clinical Epidemiology</i> , <b>2016</b> , 77, 38-43	5.7	8
40	Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. <i>Journal of Crohns and Colitis</i> , <b>2016</b> , 10, 607-18	1.5	23
39	Patterns of blood component use in cirrhosis: a nationwide study. <i>Liver International</i> , <b>2016</b> , 36, 522-9	7.9	36
38	Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy. <i>Hepatology</i> , <b>2016</b> , 64, 682-3	11.2	2
37	Oral janus kinase inhibitors for maintenance of remission in ulcerative colitis. <i>The Cochrane Library</i> , <b>2016</b> ,	5.2	1
36	Study protocol: first nationwide comparative audit of acute lower gastrointestinal bleeding in the UK. <i>BMJ Open</i> , <b>2016</b> , 6, e011752	3	4
35	Treatment Targets in Ulcerative Colitis. <i>Gastroenterology</i> , <b>2016</b> , 151, 1030-1032	13.3	
34	Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. <i>Lancet, The</i> , <b>2015</b> , 386, 137-44	40	143
33	Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial. <i>BMJ Open</i> , <b>2015</b> , 5, e007230	3	40
32	Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 1200-10	6.1	71
31	Extending evidence for the use of tranexamic acid from traumatic haemorrhage to other patients with major bleeding: do we need more than one haemorrhage protocol? The case of gastrointestinal bleeding. <i>Transfusion Medicine</i> , <b>2015</b> , 25, 198-200	1.3	1
30	Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 1158-69	6.1	36
29	Acute variceal haemorrhage in the United Kingdom: patient characteristics, management and outcomes in a nationwide audit. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 419-26	3.3	59
28	Thrombosis in inflammatory bowel disease: are we tailoring prophylaxis to those most at risk?. <i>Journal of Crohns and Colitis</i> , <b>2014</b> , 8, 166-71	1.5	18
27	New oral anticoagulants in patients with atrial fibrillation. <i>Lancet, The</i> , <b>2014</b> , 384, 24	40	
26	Poor outcomes in hospitalized patients with gastrointestinal bleeding: impact of baseline risk, bleeding severity, and process of care. <i>American Journal of Gastroenterology</i> , <b>2014</b> , 109, 1603-12	0.7	16



25	Is treatment of moderate thrombocytopenia indicated for patients with HCV infection and cirrhosis?. <i>Gastroenterology</i> , <b>2014</b> , 147, 254	13.3	
24	PTU-185 Update On The Halt-it Trial Progress: Tranexamic Acid For The Treatment Of Gastrointestinal Haemorrhage [An International, Randomised, Double Blind Placebo Controlled Trial. <i>Gut</i> , <b>2014</b> , 63, A120.1-A120	19.2	1
23	Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials. <i>Trials</i> , <b>2014</b> , 15, 456	2.8	49
22	RESTRICTIVE VERSUS LIBERAL BLOOD TRANSFUSION FOR ACUTE UPPER GASTROINTESTINAL BLEEDING (TRIGGER): PRAGMATIC, CLUSTER RANDOMISED, FEASIBILITY TRIAL. <i>Emergency Medicine Journal</i> , <b>2014</b> , 31, 780.1-780	1.5	1
21	HALT-IT--tranexamic acid for the treatment of gastrointestinal bleeding: study protocol for a randomised controlled trial. <i>Trials</i> , <b>2014</b> , 15, 450	2.8	73
20	OC-053 Results Of The Uk Multi-regional Audit Of Blood Component Use In Cirrhosis. <i>Gut</i> , <b>2014</b> , 63, A26.19-A26	19.2	1
19	Red blood cell transfusion is associated with increased rebleeding in patients with nonvariceal upper gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 37, 316-22	6.1	40
18	The case for universal access to tranexamic acid. <i>ISBT Science Series</i> , <b>2012</b> , 7, 173-176	1.1	1
17	National audit of the use of surgery and radiological embolization after failed endoscopic haemostasis for non-variceal upper gastrointestinal bleeding. <i>British Journal of Surgery</i> , <b>2012</b> , 99, 1672-80	5.3	44
16	Design of Clinical Trials in Gastrointestinal Bleeding <b>2012</b> , 280-303		
15	Why do mortality rates for nonvariceal upper gastrointestinal bleeding differ around the world? A systematic review of cohort studies. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2012</b> , 26, 537-43		33
14	OC-069 Rotational thromboelastometry in cirrhosis: hypercoagulable and hyperfibrinolytic. <i>Gut</i> , <b>2012</b> , 61, A30.1-A30	19.2	1
13	PWE-184 Prevalence, management and outcomes of patients with coagulopathy following acute non-variceal upper gastrointestinal bleeding. <i>Gut</i> , <b>2012</b> , 61, A371.1-A371	19.2	
12	Behandlungsergebnisse der akuten oberen nicht varikölen gastrointestinalen Blutung in Relation zum Zeitpunkt der Endoskopie: Resultate einer landesweiten Studie. <i>Endoskopie Heute</i> , <b>2012</b> , 25, 196-204		
11	Outcomes following acute nonvariceal upper gastrointestinal bleeding in relation to time to endoscopy: results from a nationwide study. <i>Endoscopy</i> , <b>2012</b> , 44, 723-30	3.4	66
10	Improving outcomes from acute upper gastrointestinal bleeding. <i>Gut</i> , <b>2012</b> , 61, 1246-9	19.2	26
9	Mesenchymal stromal cells (MSC) for treating immune-mediated inflammation post-transplantation and in autoimmunity. <i>The Cochrane Library</i> , <b>2012</b> ,	5.2	2
8	PWE-295 Thrombin generation is normal in cirrhotics with acute variceal haemorrhage: results from a prospective study. <i>Gut</i> , <b>2012</b> , 61, A418-A418	19.2	3

7	PWE-294 Microparticle dependent procoagulant activity and thrombin generation is increased in patients with cirrhosis induced coagulopathy. <i>Gut</i> , <b>2012</b> , 61, A417.2-A417	19.2	1
6	The overall approach to the management of upper gastrointestinal bleeding. <i>Gastrointestinal Endoscopy Clinics of North America</i> , <b>2011</b> , 21, 657-70	3.3	9
5	Mortality from acute upper gastrointestinal bleeding in the United kingdom: does it display a "weekend effect"?. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106, 1621-8	0.7	59
4	Red blood cell transfusion practice in patients presenting with acute upper gastrointestinal bleeding: a survey of 815 UK clinicians. <i>Transfusion</i> , <b>2011</b> , 51, 1940-8	2.9	20
3	PTH-019 Mortality from acute upper gastro-intestinal bleeding in the UK: does it display a weekend effect?. <i>Gut</i> , <b>2010</b> , 59, A130.1-A130	19.2	
2	OC-023 Can we predict length of stay in patients admitted with acute upper gastrointestinal bleeding?. <i>Gut</i> , <b>2010</b> , 59, A10.1-A10	19.2	
1	PTH-020 Acute upper gastrointestinal bleeding: why do patients die?. <i>Gut</i> , <b>2010</b> , 59, A130.2-A131	19.2	